BLA 125499 · Biogen Idec INC
Plegridy
Peginterferon Beta-1a · Injection · Interferon beta
NovelLast checked: Nov 20, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 15, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
22
8 Phase 3, 0 recruiting
FAERS reports
13,098
5,630 serious, 336 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 12, 2025.
PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )
Mechanism: The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 29, 2021 Supplement 21 · Efficacy LabelLetter
- Mar 27, 2020 Supplement 18 · Efficacy LetterLabel
- Aug 15, 2014 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- PLEGRIDY · PEGINTERFERON BETA-1A 125MICROGRAMS/0.5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Peginterferon Beta-1a" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00906399 · 1,516 participants · Start Jun 2009 · Primary completion Oct 2012
Drug: BIIB017 (peginterferon beta-1a); Placebo · For: Relapsing Multiple Sclerosis
Sites: Phoenix, Arizona; Ponte Vedra Beach, Florida; Atlanta, Georgia · 178 sites in all
- The Containing Coronavirus Disease 19 (COVID-19) TrialPivotal-lookingCompleted
Pontificia Universidad Catolica de ChileAcademic, hospital or other
NCT04552379 · 1,173 participants · Start Dec 1, 2020 · Primary completion May 31, 2021
Drug: Peginterferon beta-1a · For: SARS-CoV Infection; Interferon; Covid19
Sites: Santiago, Chile
- Long-Term Safety and Efficacy Study of Peginterferon Beta-1aPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT01332019 · 1,077 participants · Start Apr 2011 · Primary completion Oct 2015
Drug: peginterferon beta-1a · For: Relapsing Multiple Sclerosis
Sites: Atlanta, Georgia; Lexington, Kentucky; Baltimore, Maryland · 151 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT01939002 · 251 participants · Start Nov 2013 · Primary completion Oct 2015
Drug: BIIB017; naproxen · For: Relapsing Multiple Sclerosis
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 38 sites in all
BiogenBiogen (BIIB)
NCT02587065 · 193 participants · Start Feb 3, 2016 · Primary completion Oct 2, 2017
Drug: peginterferon beta-1a · For: Relapsing-Remitting Multiple Sclerosis (RRMS)
Sites: Arezzo, Italy; Bari, Italy; Cagliari, Italy · 30 sites in all
- A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisPivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyIndustry
NCT00441103 · 180 participants · Start Dec 2006 · Primary completion Nov 2008
Drug: Rebif® New Formulation (IFN-beta-1a, RNF); Placebo and 1 more · For: Multiple Sclerosis, Relapsing-Remitting
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple SclerosisPivotal-lookingCompleted
CinnagenIndustry
NCT05242133 · 168 participants · Start Dec 20, 2017 · Primary completion Apr 27, 2022
Drug: Pegylated interferon beta-1a; Interferon Beta-1A Prefilled Syringe · For: Relapsing Remitting Multiple Sclerosis (RRMS)
Sites: Tehran, Iran
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- influenza like illness1,470
- injection site erythema1,065
- multiple sclerosis relapse979
- fatigue715
- headache619
- pain609
- injection site reaction580
- device malfunction572
- multiple sclerosis566
- pyrexia522
- memory impairment474
- malaise471
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 18 |
| 2015 | 646 |
| 2016 | 2,699 |
| 2017 | 1,997 |
| 2018 | 1,831 |
| 2019 | 1,326 |
| 2020 | 1,077 |
| 2021 | 919 |
| 2022 | 808 |
| 2023 | 610 |
| 2024 | 463 |
| 2025 | 465 |
| 2026 | 238 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Plegridy* (PEGinterferon Beta-1a)
2024 spending
$5.6M
Beneficiaries
89
536 claims
Per beneficiary
$63,164
$8,104.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,407,505 |
| 2021 | $8,642,617 |
| 2022 | $8,056,429 |
| 2023 | $6,466,500 |
| 2024 | $5,621,558 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Multiple sclerosis clinical decision support system based on projection to reference datasets.
Ed-Driouch C, Chéneau F, Simon F, et al. · Ann Clin Transl Neurol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.
Hendin B, Huang D, Wray S, et al. · Neurodegener Dis Manag 2017 · Clinical Trial, Phase III, Multicenter Study
- Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Calabresi PA, Arnold DL, Sangurdekar D, et al. · Mult Scler 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
Shaygannejad V, Ashtari F, Saeidi M, et al. · Mult Scler Relat Disord 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study.
Zhao Y, Mokliatchouk O, Ramia NF, et al. · Med 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies.
Śladowska K, Mokko P, Brzostek T, et al. · Mult Scler Relat Disord 2025 · Systematic Review
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.